Promising combo tackles rare sarcoma in early trial

NCT ID NCT05099666

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, lurbinectedin and doxorubicin, in people with advanced soft-tissue sarcoma or leiomyosarcoma that cannot be cured with standard treatments. The first part finds a safe dose, and the second part compares the combination to lurbinectedin alone to see which works better at slowing cancer growth. About 62 adults with measurable disease are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LEIOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyosarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LEIOMYOSARCOMA ADVANCED SOFT TISSUE SARCOMA LEIOMYOSARCOMA METASTATIC METASTATIC SOFT-TISSUE SARCOMA

Contacts and locations

Show contact details

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02115, United States
Mayo Arizona

Phoenix, Arizona, 85054, United States
Mayo Jacksonville

Jacksonville, Florida, 32224, United States
Mayo Rochester

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering

New York, New York, 10065, United States